
Pfizer Inc.
PFENYSEHealthcareDrug Manufacturers - General
Previous close
$28.07
+$0.28 · +1.01%
PFE company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
78
Undervalued
Momentum
36
Weakening
Sentiment
48
Mixed
Risk resilience
82
Low Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websitePfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Albert Bourla
- Listed since
- Jun 1, 1972
- Employees
- 75,000
Market position
Day range
Current $28.07
52-week range
Current $28.07
- Open
- $27.77
- Previous close
- $27.79
- Volume
- 37.07M
- 0.92× average
- Average volume
- 40.34M
- Average daily volume
- Market cap
- 159.98B USD
- Beta
- 0.28
- Market reference 1
- 50-day average
- $25.361
- +10.68% above average
- 200-day average
- $25.9937
- +7.99% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 207.77B USD
- EV / EBITDA
- 13.76×
- Earnings yield
- 5.49%
- Free cash flow yield
- 6.41%
Profitability & efficiency
- Return on equity
- 8.99%
- Return on assets
- 3.73%
- Return on invested capital
- 8.84%
Financial health
- Current ratio
- 1.16×
- Altman Z-score
- 2.09
- Piotroski F-score
- 7 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 62.58B USD | 63.63B USD | 59.55B USD | 100.33B USD | 81.29B USD |
| Cost of goods sold | 18.57B USD | 21.78B USD | 29.21B USD | 38.24B USD | 34.41B USD |
| Gross profit | 44.01B USD | 41.85B USD | 30.34B USD | 62.09B USD | 46.88B USD |
| Research and development | 11.98B USD | 10.74B USD | 10.58B USD | 11.43B USD | 13.83B USD |
| Selling, general, and administrative | 13.35B USD | 14.73B USD | 14.47B USD | 13.12B USD | 12.25B USD |
| Operating expenses | 28.58B USD | 25.36B USD | 25.05B USD | 24.54B USD | 26.08B USD |
| Interest income | 603M USD | 545M USD | 1.62B USD | 251M USD | 36M USD |
| Interest expense | 2.67B USD | 3.09B USD | 2.21B USD | 1.24B USD | 1.29B USD |
| Depreciation and amortization | 4.91B USD | 7.01B USD | 6.29B USD | 5.06B USD | 5.19B USD |
| Operating income | 15.44B USD | 16.48B USD | 5.29B USD | 37.55B USD | 20.79B USD |
| Net income | 7.77B USD | 8.02B USD | 2.13B USD | 31.37B USD | 22.15B USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- 1.36
- FY2025 · -3.55% year over year
- Latest fiscal-year revenue
- 62.58B USD
- FY2025 · -1.65% year over year
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
39 ratingsRecent analyst actions
PFE news
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
$1.72
2025 complete year+10.3% since 2021
2026 partial: $1.29
$1.56
2,021
$1.60
2,022
$1.64
2,023
$1.68
2,024
$1.72
2,025
$1.29
2,026*
* Partial calendar year in the available dividend history.
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jul 24, 2026 | $0.43Quarterly | Jul 24, 2026 | Sep 1, 2026 |
Dividend | May 8, 2026 | $0.43Quarterly | May 8, 2026 | Jun 12, 2026 |
Dividend | Jan 23, 2026 | $0.43Quarterly | Jan 23, 2026 | Mar 6, 2026 |
Dividend | Nov 7, 2025 | $0.43Quarterly | Nov 7, 2025 | Dec 1, 2025 |
Dividend | Jul 25, 2025 | $0.43Quarterly | Jul 25, 2025 | Sep 2, 2025 |
Dividend | May 9, 2025 | $0.43Quarterly | May 9, 2025 | Jun 13, 2025 |
Ex-dividend Jul 24, 2026
$0.43
Quarterly
Record Jul 24, 2026 · Payment Sep 1, 2026
Ex-dividend May 8, 2026
$0.43
Quarterly
Record May 8, 2026 · Payment Jun 12, 2026
Ex-dividend Jan 23, 2026
$0.43
Quarterly
Record Jan 23, 2026 · Payment Mar 6, 2026
Ex-dividend Nov 7, 2025
$0.43
Quarterly
Record Nov 7, 2025 · Payment Dec 1, 2025
Ex-dividend Jul 25, 2025
$0.43
Quarterly
Record Jul 25, 2025 · Payment Sep 2, 2025
Ex-dividend May 9, 2025
$0.43
Quarterly
Record May 9, 2025 · Payment Jun 13, 2025
PFE peers
ETFs holding PFE
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.54B0.20%2.3T USD0.03%$378.24+0.44%
Vanguard S&P 500 ETFVOO3.74B0.22%1.7T USD0.03%$703.71+0.39%
iShares Core S&P 500 ETFIVV2.13B0.24%891.84B USD0.03%$769.31+0.39%
State Street SPDR S&P 500 ETFSPY1.97B0.24%817.87B USD0.09%$765.72+0.41%
Vanguard Morningstar Value ETFVTV1.36B0.53%256.5B USD0.03%$226.4+0.54%
State Street Health Care Select Sector SPDR ETFXLV1.14B2.55%44.76B USD0.08%$174.62+1.29%
iShares Core High Dividend ETFHDV702.87M4.58%15.39B USD0.08%$29.81+0.27%
Vanguard High Dividend Yield ETFVYM573.41M0.58%99.2B USD0.04%$164.97+0.59%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 4.54B
- Weight
- 0.20%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard S&P 500 ETFVOO- Market value
- 3.74B
- Weight
- 0.22%
- AUM
- 1.7T USD
- Expense ratio
- 0.03%
- Price / 1D
- $703.71+0.39%
iShares Core S&P 500 ETFIVV- Market value
- 2.13B
- Weight
- 0.24%
- AUM
- 891.84B USD
- Expense ratio
- 0.03%
- Price / 1D
- $769.31+0.39%
State Street SPDR S&P 500 ETFSPY- Market value
- 1.97B
- Weight
- 0.24%
- AUM
- 817.87B USD
- Expense ratio
- 0.09%
- Price / 1D
- $765.72+0.41%
Vanguard Morningstar Value ETFVTV- Market value
- 1.36B
- Weight
- 0.53%
- AUM
- 256.5B USD
- Expense ratio
- 0.03%
- Price / 1D
- $226.4+0.54%
State Street Health Care Select Sector SPDR ETFXLV- Market value
- 1.14B
- Weight
- 2.55%
- AUM
- 44.76B USD
- Expense ratio
- 0.08%
- Price / 1D
- $174.62+1.29%
iShares Core High Dividend ETFHDV- Market value
- 702.87M
- Weight
- 4.58%
- AUM
- 15.39B USD
- Expense ratio
- 0.08%
- Price / 1D
- $29.81+0.27%
Vanguard High Dividend Yield ETFVYM- Market value
- 573.41M
- Weight
- 0.58%
- AUM
- 99.2B USD
- Expense ratio
- 0.04%
- Price / 1D
- $164.97+0.59%
Continue in GoAI
Research PFEresearch.disclaimer











